Sign up to save your podcasts
Or
Share Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.
Further Listening:
Trillion Dollar Shot
Why WeightWatchers Wants in on Drugs Like Ozempic
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By The Wall Street Journal & Spotify Studios
4.2
55465,546 ratings
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.
Further Listening:
Trillion Dollar Shot
Why WeightWatchers Wants in on Drugs Like Ozempic
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More shows like The Journal.
View all
Planet Money
30,646 Listeners
WSJ Opinion: Potomac Watch
2,828 Listeners
WSJ Your Money Briefing
1,719 Listeners
WSJ What’s News
4,358 Listeners
WSJ Tech News Briefing
1,638 Listeners
The Daily
112,539 Listeners
WSJ Minute Briefing
673 Listeners
Up First from NPR
56,431 Listeners
Bold Names
1,448 Listeners
The Indicator from Planet Money
9,513 Listeners
Today, Explained
10,227 Listeners
Post Reports
5,452 Listeners
Barron's Streetwise
1,549 Listeners
Bad Bets
1,322 Listeners
WSJ Opinion: Free Expression
608 Listeners
As We Work
151 Listeners
WSJ's Take On the Week
146 Listeners